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Abstract
A consensus workshop on low-calorie sweeteners (LCS) was held in November 2018 where seventeen experts (the panel) discussed three
themes identified as key to the science and policy of LCS: (1) weight management and glucose control; (2) consumption, safety and perception;
(3) nutrition policy. The aims were to identify the reliable facts on LCS, suggest research gaps and propose future actions. The panel agreed that
the safety of LCS is demonstrated by a substantial body of evidence reviewed by regulatory experts and current levels of consumption, even for
high users, are within agreed safety margins. However, better risk communication is needed. More emphasis is required on the role of LCS in
helping individuals reduce their sugar and energy intake, which is a public health priority. Based on reviews of clinical evidence to date, the
panel concluded that LCS can be beneficial for weight management when they are used to replace sugar in products consumed in the diet
(without energy substitution). The available evidence suggests no grounds for concerns about adverse effects of LCS on sweet preference,
appetite or glucose control; indeed, LCS may improve diabetic control and dietary compliance. Regarding effects on the human gut microbiota,
data are limited and do not provide adequate evidence that LCS affect gut health at doses relevant to human use. The panel identified research
priorities, including collation of the totality of evidence on LCS and body weight control, monitoring and modelling of LCS intakes, impacts on
sugar reduction and diet quality and developing effective communication strategies to foster informed choice. There is also a need to reconcile
policy discrepancies between organisations and reduce regulatory hurdles that impede low-energy product development and reformulation.
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Introduction and aim of the Consensus Report
A number of reviews, some narrative and some systematic, have
discussed the evidence for the safety of low-calorie sweeteners
(LCS) and their effects on appetite, food intake, body weight,
glucose control and other health outcomes(1–8). Evidence has
also been evaluated by authorities, such as the European
Food Safety Authority (EFSA), the (US) Dietary Guidelines
Advisory Committee, the French Agency for Food,
Environmental and Occupational Health & Safety (ANSES) and
Public Health England, who have issued statements or opinions
on the use of LCS(9–13). Other groups of scientific experts have
generated consensus statements, position papers, or other state-
ments on LCS. These include the British Dietetic Association,
Diabetes UK, the American Heart Association and American
Diabetes Association (AHA/ADA)(14–20).
This paper describes the results of a workshop in which sev-
enteen experts convened to discuss and debate the science and
policy relating to the use of LCS. The aims were to establish, via
consensus-forming techniques, clear and simple statements on
LCS that all the panel agreed (facts), to highlight the areas where
more research is required (gaps) and to propose how progress
might be achieved (actions). It is hoped that the provision of
these statements on safety and potential benefits of LCSwill assist
health practitioners and policy makers to promote consistent
messages and develop strategies based on sound science.
Identification of the gaps and actions will help promote better
study designs, suggest priorities for research funding and
thereby encourage more coherent public health policy.
Background to low-calorie sweeteners and their
regulatory approval process
All LCS have undergone an extensive safety evaluation process
by international and national regulatory food safety bodies both
before and after their approval for use in the market. The FAO/
WHO Joint Expert Committee on Food Additives (JECFA)(21), the
US Food and Drug Administration (FDA)(22) and EFSA(9) have
confirmed the safety of all approved LCS as food additives.
Hence there is an extensive body of evidence from both animal
models and human studies that support the safety of LCS. Each
compound is considered individually as their characteristics,
metabolism and metabolic fates are different(23). Furthermore,
there is an ongoing review process to ensure that any new
information on safety is evaluated, for example recent scientific
opinions by EFSA on aspartame and sucralose(24,25).
As part of the LCS safety evaluations, the regulatory author-
ities establish the Acceptable Daily Intakes (ADI) for each
sweetener(26). The ADI is defined as an estimate of the amount
of a food additive, expressed per kg body weight, that can be
ingested daily by individuals over a lifetime without appreciable
risk to health. ‘Without appreciable risk’ means, based on the
current knowledge, ‘certainty that no harm will result, even after
a lifetime of exposure to the additive’(27). The current ADI for LCS
were established using the ‘no observed adverse effect level’
(NOAEL). This is the highest dietary level of an additive at which
no adverse effects were observed in animal studies. The ADI is
typically set at 1/100th of the NOAEL (10-fold reduction for
inter-species variation and 10-fold reduction for intra-species
variation) to give a large margin of safety for even the most sen-
sitive consumer. The ADI refers to a lifelong exposure situation,
not a single occasion, and thus infrequent consumption of levels
higher than the ADI are not a health concern. Because of the
large safety margin used in setting the ADI, it is likely that an
ADI for a given additive would have to be exceeded by some
considerable amount for an extended period of time for there
to be any risk of harm to human health. However, if an intake
estimate indicates that the ADI may be regularly exceeded by
certain sectors of the population, the regulatory authority may
advise a reduction of levels in foods, or to reduce the range of
foods in which the additive is permitted for use(27). In some
cases, the ADI may be ‘not specified’ when the total potential
intake from all possible sources does not represent a hazard
to health, and hence no numerical ADI is needed. It should
be noted that, in the future, the benchmark dose (BMD) will
be the preferred approach for establishing a reference point(28).
However, discussion of the expert considerations and data
requirements for calculation of a BMD is beyond the scope of
this paper.
In relation to efficacy, EFSA has a system for evaluating
dossiers of evidence submitted for the substantiation of health
claims(29). In 2011, the EFSA Panel on Nutrition, Novel Foods
and Food Allergens concluded that there was sufficient scientific
evidence to support the claims that intense sweeteners, like all
sugar replacers, lead to a lower rise in blood sugar levels
after meals if consumed instead of sugars, and maintain tooth
mineralisation by decreasing tooth demineralisation; again, if
consumed instead of sugars. However, at that time, EFSA’s
experts found no clear cause-and-effect relationship to substan-
tiate the claims that intense sweeteners when replacing sugars
maintain normal blood sugar levels, or maintain/achieve a nor-
mal body weight(30).
There are currently various jurisdiction-specific restrictions
on the use of LCS in foods and beverages. For example, under
European legislation, sweeteners are only permitted if used to
replace sugars for the production of energy-reduced food (i.e.
with 30 % less energy), non-cariogenic food, or food with no
added sugars(31). This limits the options available to manufac-
turers for more modest reformulation or stepwise reduction of
sugar content in food and drink through the use of sweeteners.
Methods
The consensus workshop was designed to follow a conference
held by the International Sweeteners Association (ISA) in
London on 6 November 2018 entitled ‘The science behind low
calorie sweeteners: where evidence meets policy’. The panel
members were all speakers or chairs at that conference, chosen
for their international expertise in LCS science and policy. The
workshop was chaired and facilitated by two independent con-
sultants in nutrition science (M. A. and S. G.), who drafted the
paper and coordinated responses fromparticipants. The ISA pro-
vided funds for the venue and speakers’ expenses. They were
observers at the workshop but had no control over the paper.
Disclosures of interest for all authors are given.
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The workshop leaders (M. A. and S. G.) identified three key
themes or topic areas for discussion at the workshop:
(1) Role of low-calorie sweeteners in weight management and
glucose control;
(2) Consumption and safety of low-calorie sweeteners and con-
sumer perception;
(3) Role of low-calorie sweeteners in relation to nutrition policy.
As the workshop was time-limited the choice of themes was
based on the pertinence in terms of current debates on LCS, and
the available expertise represented by the panel.
Before the workshop, each panel member was asked to pro-
vide feedback on three questions with respect to their own area
of expertise:
(a) Statements of fact: what do we know?
(b) Questions and type of evidence needed (gaps: what do we
still need to know?)
(c) How this might translate to further research work or policy
(actions: what should we do?).
Comments were minimally edited by M. A. and S. G. to
produce the working document with provisional statements/
questions/actions for each theme.
At the workshop all the participants discussed the working
document in detail. A scoring system (1= strongly disagree to
10= strongly agree) was used to evaluate level of agreement
on the ‘facts’. Statements that achieved a high level of agreement
were discussed further. Participants refined the wording of each
statement to reach consensus. Having established agreement on
the facts, participants identified the major gaps or research
questions. Finally, participants identified the most important
‘actions’ suggested in the working document and these were
then summarised. Participants agreed to the process for further
review and publication, i.e. that the workshop leaders would
circulate the draft consensus document for comments, integrate
responses and write the discussion before presenting the final
article to all participants for review and approval. Table 1 shows
the timeline of the project.
Results
The results are given below in the form of the consensus state-
ments for the three themes and the three questions relating to
each theme. The panel agreed the most pertinent references
to cite for each consensus statement.
Theme 1: Role of low-calorie sweeteners in weight
management and glucose control: the scientific evidence
1a Facts: what we know
(1) When substituted for sugars to reduce energy density of
foods and drinks, LCS reduce net energy intake and assist
weight management(3,5,12,13).
(2) Intervention studies have shown that beverages containing
LCS have at least a similar effect on appetite and energy
intake to water(5,32).
(3) The collective evidence supports the conclusion that LCS
have no adverse effect on blood glucose and insulin regu-
lation (HbA1c, fasting and postprandial glucose and insulin
levels) in individuals with, and without, diabetes(2,33,34).
(4) The potential value of LCS in dietary management of diabe-
tes derives from their role as substitutes for sugars, and
hence carbohydrates(19).
(5) Confounding by adiposity, and reverse causality can
explain the positive association between LCS and type 2
diabetes and other cardiometabolic diseases, reported in
some observational studies(35–37).
(6) Regarding effects involving the human gut microbiota, data
are limited and do not provide adequate evidence that LCS
influence gut health at doses relevant to human use(38).
1b Gaps: what we don’t know
(1) What are the long-term effects of LCS on glucose tolerance,
gut function, cardiometabolic effects, gut microbiota and
weight management?
(2) How are these effects altered according to personal factors,
such as age, sex, ethnicity, socio-economic status, health
status, diet and lifestyle?
Table 1. Timeline of the project
Date Process
January 2018 Identification of ISA conference speakers and chairs
April 2018 Workshop leaders (M. A. and S. G.) appointed
Conference speakers and chairs invited to workshop
May 2018 Three key workshop themes identified by workshop leaders
May 2018 Workshop leaders agree questions for experts based on the three themes for workshop
July 2018 Experts asked to provide provisional answers to questions
September 2018 Workshop leaders collate expert comments into working document
6 November 2018 ISA conference
7 November 2018 Expert workshop
November 2018 Draft consensus statements agreed at workshop, circulated to experts
December 2018 Comments received from experts
December 2018–January 2019 Draft paper written by workshop leaders
January 2019 Draft paper circulated to experts for approval
February 2019 Paper finalised and submitted to journal
July and August 2019 Revisions to paper agreed by panel
ISA, International Sweeteners Association.
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(3) How do these effects differ according to dietary context
(ad libitum v. weight-control diet) and form of LCS (in
liquids or solids), and type or blend of LCS?
(4) Does reducing exposure to sweetness have consequences
for food choice and intake in the medium to long term?
(5) Can LCS help improve long-term type 2 diabetes manage-
ment, when part of standard dietary and lifestyle
approaches?
1c Actions: what should be done?
(1) There is a need for a portfolio of well-designed randomised
controlled trials (with an appropriate time-frame of 1 year or
more) with different comparators and different carriers of
LCS (food and beverage matrices). The trials should be
conducted by level of ‘free sugar’ intake in different popu-
lations; they should usemultiple endpoints (diet quality, gut
microbiota function and metabolomics, and wider health
and quality of life measures). They should be done in the
context ofweight-control diets, including for type 2 diabetes
and also in non-restrictive diets.
(2) There is a need for population cohort studies to model
changes in weight/cardiometabolic risk in the context of
changes in LCS consumption, not baseline LCS values.
The studies should include substitution analysis (for
example, LCS beverages for energy beverages, water,
etc.) and adjustment for adiposity. Their data should be
made available for further analysis.
(3) There is a need for a collation of evidence to support future
health claim submissions for LCS and body weight control,
as data become available.
Theme 2: Consumption and safety of low-calorie
sweeteners and consumer perception
2a Facts: what we know
(1) The safety of LCS is demonstrated by a substantial body of
evidence as well as continued review by independent regu-
latory agencies/committees including JECFA/Codex, FDA
and EFSA(9,21,22). These organisations have taken into
account the decades of both positive and negative human
and animal studies to draw their conclusions. Continual
monitoring and modelling of LCS exposures is undertaken
and this demonstrates that intakes of LCS, even among high
consumers, are within ADI(39–41).
(2) Currently, the major sources of LCS in the Western diet are
beverages and table-top sweeteners(39,40,42).
(3) LCS can be used to reduce the sugar and energy content of
beverages and some foods whilst maintaining a similar
sensory profile. The potential for energy reduction is more
limited in foods and depends on the options for reformula-
tion andwhat replaces the bulk of sugar(43). LCS can be used
synergistically in blends to achieve the desired sensory
profile at lower levels of use.
(4) The collective evidence supports the conclusion that there
is no relationship between adiposity and liking/preference
for sweet taste in either adults or children(44).
(5) Consumer perceptions vary with regard to LCS, with some
individuals having concerns about their potential health
effects(14,20).
2b Gaps: what we don’t know
(1) Which factors (including knowledge, attitudes and
behaviours) influence consumer perception of risks and
benefits of LCS consumption? Are these the same for health
professionals?
(2) There is a need for in-depth data relating to current patterns
of LCS consumption at multiple levels, and across countries
and regions, to strengthen the evidence base.
(3) There is a need for more reliable measures of LCS exposure,
such as biomarkers. Further development of these and better
linkage of food composition and dietary databases are needed
to help monitor changing use and consumption of LCS.
2c Actions: what should be done?
(1) There is a need to research and develop evidence-based
strategies to communicate all of the above to consumers,
health professionals and policymakers. The extensive body
of scientific evidence that backs regulatory approval and the
ongoing safety assessment of LCS can then encourage
better-informed public health decisions. Themedia or other
organisations could be provided, for example, with simple
explanations of the ADI.
(2) There is a need to develop communications to foster more
informed public attitudes towards LCS, for example by
emphasising the potential health gains associated with
sugar (and energy) intake reduction and the role of LCS
in achieving this. It is important to explain that the overall
impact of LCSwill depend on the amount of sugars replaced
in the diet and the overall reduction in calorie (energy)
intake that ensues. Use of LCS alone cannot be expected
to act as a ‘silver bullet’ for weight loss.
(3) Research into biomarkers for individual LCS is needed to
complement the exposure assessment based on consump-
tion records. There is a need to improve linkage of data-
bases and to model intakes in future scenarios.
Theme 3: Role of low-calorie sweeteners in relation to
nutrition policy
3a Facts: what we know
(1) Reduction in the intake of ‘free sugars’ and ‘added sugars’ is
being recommended around the world to reduce the risk
and prevalence of obesity, which is a major public health
concern(10,45,46). LCS is one of the strategies to consider.
(2) LCS can be useful in dietary approaches to both prevent and
manage diabetes and obesity. Benefit will depend on how
foods and beverages containing LCS are substituted, as well
as on the overall quality of the diet and the overall energy
provision(16).
(3) Despite repeated and consistent reassurances from food
safety authorities, there is still some distrust of LCS among
health professionals and policy makers(47).
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(4) Some policies acknowledge LCS consumption as a useful
strategy to reduce sugars intake(12). However, there are
discrepancies with other national and international
policies(10,11) and regarding use in children.
3b Gaps: what we don’t know
(1) Can LCS help individuals meet the population-level dietary
recommendations for reduction of sugars intake (for exam-
ple, to 5 % (average)(48) or 10 % (for individuals)(10,45))? If so,
how can this be achieved?
(2) How does a dietary approach that includes LCS-sweetened
foods and drinks affect dietary quality compared with low-
sugar diets?
(3) What are the best strategies to communicate LCS safety and
efficacy to interested parties such as health professionals
and the general public?
3c Actions: what should be done?
(1) There is a need to model the potential for LCS to reduce
sugar content and sugar intakes whilst ensuring that other
dietary recommendations can also bemet in the overall diet.
(2) Trends in dietary intake of LCS need to bemonitored, linked
with food and beverage reformulation and ultimately with
health outcomes.
(3) Policies relating to LCS from different countries should be
reviewed to compare their remit, priorities, evidence base
and interpretation.
(4) To help reconcile policy discrepancies, policy makers, sci-
entists and regulatory affairs experts should agree on their
understanding of the role of LCS in the diet.
(5) In the context of sugar reduction and obesity, it would be
helpful to review the regulatory and public health policy
hurdles that prevent wider use of LCS in food products
for those sweeteners where dietary intake is very low com-
pared with the ADI.
Discussion
Strengths and limitations of approach
The methodology followed a planned and transparent process.
All seventeen experts were requested ahead of the workshop to
generate a summary of their topic in the form of answers to the
three questions. Thesewere then collated under three themes by
the workshop leaders and combined for the working document,
which was circulated before the workshop. At the start of the
group discussion, scoringwas used as a consensus-forming tech-
nique to allow participants to indicate the strength of their agree-
ment with each statement. Alternative forms of wording
suggested by participants were considered in order to improve
clarity of each statement. The resulting statements were circu-
lated after the workshop, with supporting references, to allow
for further reflection and improvement. A strength of the process
was the expertise represented on the panel in many aspects of
LCS (including toxicology, regulation, food science, medicine,
microbiology, psychology, epidemiology, public health nutri-
tion and dietetics). Finally, holding the workshop immediately
after a scientific conference on the topic ensured that all experts
were fully prepared and engaged to discuss the issues and for-
mulate consensus.
The workshop was wide in scope but was not intended to be
exhaustive; the themes were selected as being pertinent to cur-
rent debate on LCS and within scope of the expertise of the
panel. Consensus was based on expert opinion and key referen-
ces including systematic reviews; the group did not review all the
primary literature on these themes. Other possible limitations of
the methodology were that all our participants were scientists or
public health experts, unlike the broader stakeholder panel used
by Bright et al.(49). The workshop was instigated and funded by
ISA; however, ISA had no control over the choice of themes, and
no role in the discussion or this paper. Participants all acted com-
pletely independently to express their views in open debate and
to contribute to the resulting paper.
Comparison with other consensus papers relating to low-
calorie sweeteners
Goals and methodology. To our knowledge, there have been
three previous papers published in English that contain consen-
sus statements about LCS(14,15,49). In addition, there have been a
number of position papers and evidence reviews whose meth-
odology and scope differ from that of the present report and
these are discussed later.
The goal of the consensus report by Gibson et al.(14) was to
summarise the role and potential benefits of LCS on appetite,
energy intake, body weight, diabetes and dental health to give
clarity to health professionals and educators on the use of
LCS. The goal of the Ibero–American Consensus on LCS(15)
was ‘to develop a consensus on the use of low- and no-calorie
sweeteners as substitutes for sugars and other energy sweeteners
in line with current international public health recommenda-
tions, in the context of the prevention and treatment of obesity
and related diseases in Latin American countries’. The report(15)
also provides a comprehensive overview of the position of
international and national regulatory bodies on LCS safety and
efficacy studies on individual LCS. Both these consensus
reports(14,15) were compiled by panels limited to international
scientists and public health experts.
The report by Bright et al.(49) focused on future research
needs, and involved a wider stakeholder panel who participated
in interactive webinars, surveys and interviews with the research
team and generated a list of eighteen questions across five broad
research areas, ranking them in order of priority. The stake-
holder panel was recruited according to the ‘7 P’s’ of stakeholder
engagement, i.e. patients, providers, researchers, policymakers,
product makers, payers, and purchasers(50). It therefore included
policymakers, lay audience members, health providers, a
research funder, individuals with food industry experience,
and researchers of several different specialties.
Content and conclusions. The consensus statements agreed by
our expert panel were produced independently but have been
compared with previous consensus statements in Table 2.
Further details can be found in online Supplementary Tables
S1 and S2. Some topics were not covered in other reports: for
example, the statements in this paper have included association
Expert consensus on low-calorie sweeteners 5
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between sweetness preference and obesity, effects of LCS on
gut bacteria and sources of LCS, which were not covered by
Gibson et al.(14) or Serra-Majem et al.(15); conversely, this panel
did not consider the effects of LCS on dental health.
Table 2 shows there was broad agreement between the senti-
ments expressed in our statements and these two reports.
The gaps identified byour panel have been comparedwith the
research priorities from Bright et al.(49) (online Supplementary
Table S3). Most of the important future research questions iden-
tified by their stakeholder panel were also selected by our panel
as areas in need of study. In the case of effects of LCS beverages on
appetite and energy intake, our panel considered the evidence to
be sufficiently strong for ‘no effect or at least similar effect’ com-
pared with water to be classed as fact, and for a reduction in
energy intake compared with sugar also to be classed as fact.
Research gaps identified by our panel and not identified by
Bright et al.(49) included research on biomarkers of LCS
consumption to aid intake assessments, research on communica-
tion with consumers and other stakeholders about LCS and more
research on issues related to policy. Conversely Bright’s(49) ques-
tions on the sensing of LCS by the brain and the impact of LCS on
the fetus did not feature directly in our workshop discussion.
Comparison with other reviews and position statements. In
2011 EFSA was of the opinion that a cause-and-effect relation-
ship had not been established between the use of intense
sweeteners and maintenance of normal body weight or blood
glucose, but several high-quality studies and reviews have since
been published(51–54) and others are currently underway: the
SWITCH project(55) and the SWEET project (available at
https://sweetproject.eu). A number of reviews and position
statements have addressed the evidence for and against health
benefits of LCS. Our panel observed that differences between
the positions and policies of different organisations with regard
Table 2. Comparison of our consensus statements on low-calorie sweeteners (LCS) with those of others
Consensus statements
Gibson et al.
(2014)(14)
Serra-Majem et al.
(2018)(15)
Theme 1: Role of low-calorie sweeteners in weight management and glucose control: the scientific evidence
1. When substituted for sugars to reduce energy density of foods and drinks, LCS can reduce net energy
intake and assist weight management
þ þ
2. Intervention studies have shown that LCS beverages have at least a similar effect on appetite and energy
intake to water
þ
3. The collective evidence supports the conclusion that LCS have no adverse effect on blood glucose and
insulin regulation (HbA1c, fasting and postprandial glucose and insulin levels) in individuals with, and without,
diabetes
þ þ
4. The potential value of LCS in dietary management of diabetes derives from their role as substitutes for
sugars. and hence carbohydrates
þ þ
5. Confounding by adiposity, and reverse causality can explain the positive association between LCS and
type 2 diabetes and other cardiometabolic diseases, reported in some observational studies
þ
6. Regarding effects involving the human gut microbiota, current evidence is limited and does not provide
adequate evidence that LCS influence gut health at doses relevant to human use
Theme 2: Consumption and safety of low-calorie sweeteners and consumer perception
1. The safety of LCS is demonstrated by a substantial body of evidence as well as continued review by
independent regulatory agencies/committees including JECFA/Codex, FDA and EFSA. These organisations
have taken into account the decades of both positive and negative human and animal studies to draw their
conclusions. Continual monitoring and modelling of LCS exposures are undertaken and this demonstrates
that intakes of LCS, even among high consumers, are within ADI
þ
2. Currently, the major sources of LCS in the Western diet are beverages and table-top sweeteners
3. LCS can be used to reduce the sugar and energy content of beverages (and some foods) whilst
maintaining a similar sensory profile. The potential for energy reduction is more limited in foods and depends
on the options for reformulation and what replaces the bulk of sugar. LCS can be used synergistically in
blends to achieve the desired sensory profile at lower levels of use
þ þ
4. The collective evidence supports the conclusion that there is no relationship between adiposity and liking/
preference for sweet taste in either adults or children
5. Consumer perceptions vary with regard to LCS, with some individuals having concerns about their
potential health effects
þ þ
Theme 3: Role of low-calorie sweeteners in relation to nutrition policy
1. Reduction in the intake of ‘free sugars’ and ‘added sugars’ is being recommended around the world to
reduce the risk of obesity, which is a major public health concern. LCS should be one of the strategies to
consider
þ þ
2. LCS can be useful in dietary approaches to both prevent and manage diabetes and obesity. Benefit will
depend on how foods and beverages containing LCS are substituted, as well as on the overall quality of the
diet and the overall energy provision
þ þ
3. Despite repeated and consistent reassurances from food safety authorities, there is still some distrust of
LCS among health professionals and policy makers
þ þ
4. Some policies acknowledge LCS consumption as a useful strategy to reduce sugars intake However, there
are discrepancies with other national and international policies and regarding use in children
þ
þ, Broad correspondence with our consensus statements; blank, not (or not fully) addressed; JECFA, Joint Expert Committee on Food Additives; FDA, US Food and Drug
Administration; EFSA, European Food Safety Authority; ADI, Acceptable Daily Intake.
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to LCS are a cause of confusion. Reasons for discrepancies may
include different remits and approaches. The goal of systematic
review and meta-analysis is frequently hampered by differing
study designs that make comparison difficult and meta-analysis
unreliable; hence the need for cautious wording, which may be
interpreted as a negative statement. It is important to clearly
establish that LCS are food additives and, as such, cannot provide
health benefits, except in relation to the reduction of sugarwithin
an adequate diet and lifestyle. Our panel concluded that, when
used to replace dietary sugar, the use of LCS facilitates reduction
in energy intake and weight loss. This was based on evidence
from randomised controlled trials of 6 months to 2 years in length
and recent systematic reviews that pay careful attention to
appropriate comparators. The panel also stated the need for
studies of longer-term effects. By contrast, a recent wide-ranging
review on health effects of non-sugar sweeteners (which in prac-
tice were LCS as polyols were excluded) concluded that ‘there
were no significant or clinically important effects on most
outcomes’(8). However, due to very strict inclusion and exclusion
criteria, their analyses omitted some notable studies on body
weight(51–54) and combined studies with different comparators,
potentially diluting the effect size(56). Another recent review(57)
has been criticised on the same grounds(37). Toews et al.(8) also
stated that ‘potential harms from the consumption of non-sugar
sweeteners could not be excluded’, a statement which relates to
lack of evidence, not evidence of harm. Our panel took a harm-
reduction approach, where LCS are a desirable substitute for
sugar and one route to helping achieve sugar and energy reduc-
tion whilst still maintaining dietary diversity and pleasure.
Other position statements, particularly those published
before 2014, have offered cautious conclusions on potential ben-
efits of LCS. For example, the 2012 joint scientific statement from
the American Heart Association and the American Diabetes
Association (AHA/ADA) concluded that ‘at present there are
insufficient data to determine conclusively that non-nutritive
sweeteners (NNS) benefit appetite, energy intake or body
weight’(20). However, the AHA/ADA document also stated that
‘when used judiciously, NNS could facilitate reductions in added
sugars intake, thereby resulting in decreased total energy and
weight loss/weight control and promoting beneficial effects
on related metabolic parameters’.
The latest AHA advisory statement(19) (which focused on LCS
beverages and cardiometabolic outcomes) concluded that the
use of LCS beverages may be an effective strategy to help control
energy intake and promote weight loss. Nonetheless, due to the
lack of long-term trials in children, the AHA thought it prudent to
advise against prolonged consumption of LCS beverages by chil-
dren, preferring water, other unsweetened beverages or milk as
the primary drink. Policy statements from professional bodies of
dietitians and nutritionists have generally been pragmatic, seeing
LCS as a helpful tool in helping individuals reduce their sugar
intake and manage their weight in the context of a healthy bal-
anced diet that meets other dietary recommendations(16–18).
Extension of our consensus statements to actions and
policies. The main strategy of our consensus workshop was
to stimulate forward thinking as well as to restate principles.
The consensus statements on actions put the focus firmly on
what is required to deliver. For example, the panel made recom-
mendations for further long-term randomised controlled trials of
LCS with different comparators and multiple endpoints, for pro-
spective studies that control for adiposity and other
confounders, and for better estimates of LCS exposure. Such
recommendations may help research funding bodies select
priorities. Clarity and consistency of policy would be improved
by a comprehensive evaluation of all the evidence on effects of
LCS. Others have also called for larger and longer clinical trials
with careful selection of comparators(7,37,44,58). The review by
Toews et al.(8) was also critical of the size, short duration, and
methodological and reporting quality of studies. It also called
for more data on benefits and risks of non-sugar sweeteners
in doses and patterns more akin to real-life consumption(8).
Our expert panel considered the safety data to be robust but
agreed that there is a continued need for ongoing exposure
assessment to account for changing LCS use, and also consider-
ation of any new evidence that might emerge. Novel recommen-
dations made by the panel included better strategies and
methods to improve communications about the safety and
efficacy of LCS, modelling of the effect of LCS on sugar reduction
and diet quality, relaxing regulation to increase the potential for
reformulation using LCS, and review and reconciliation of policy
differences on the use of LCS.
Conclusion
The panel considered that the substantial body of evidence con-
cerning LCS safety should be communicated in a consistent man-
ner. More emphasis is required on the role of LCS in helping
individuals reduce their sugar and energy intake, which is a pub-
lic health priority.
Research priorities should include:
(a) a dossier of the totality of evidence on LCS and body weight
control;
(b) studies to monitor and model LCS intakes and their impact
on sugar reduction and diet quality;
(c) effective communication strategies to inform consumers,
non-governmental organisations (NGOs), health
professionals, research funding bodies and the food and
beverage industry.
Efforts should be made to understand and, where possible,
reconcile policy discrepancies between organisations and
reduce regulatory hurdles that impede product development
and reformulation designed to reduce sugars and/or energy.
It is hoped that these consensus statements and recommen-
dations arising from the expert workshop will assist policy
makers, and other stakeholders including NGOs, health
professionals, research funding bodies and the food and bever-
age industry.
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